Knowledge Hub
1. Cui, W., Mother or nothing: the agony of infertility. Bull World Health Organ, 2010. 88(12): p. 881-2.
2. Brugo-Olmedo, S., C. Chillik, and S. Kopelman, Definition and causes of infertility. Reprod Biomed Online, 2001. 2(1): p. 41-53.
3. Abu-Musa, A., T. Haahr, and P. Humaidan, Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. Int J Mol Sci, 2020. 21(6).
4. Klinkert ER, Broekmans FJ, Looman CW, Te Velde ER. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil Steril (2004) 81:1247–53. 10.1016/j.fertnstert.2003.10.030
5. Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, et al. Recombinant human follicle-stimulatin hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. (2014) 20:17 10.1186/1477-7827-12-17
6. Giannelou, P., et al., The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment. Diagnostics (Basel), 2020. 10(9).
7. Anitua E, Muruzabal F, Pino A, Prado R, Azkargorta M, Elortza F, Merayo-Lloves J. Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum. Int J Mol Sci. 2021 Nov 10;22(22):12176. doi: 10.3390/ijms222212176. PMID: 34830053; PMCID: PMC8618701.
8. Qureshi, A.H., et al., Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling. PLoS One, 2009. 4(10): p. e7627.
9. Graves, D.T., Y.M. Kang, and K.N. Kose, Growth factors in periodontal regeneration. Compend Suppl, 1994(18): p. S672-7; quiz S714-7.
10. Li, W., et al., Subcutaneous injections of platelet-rich plasma into skin flaps modulate proangiogenic gene expression and improve survival rates. Plast Reconstr Surg, 2012. 129(4): p. 858-866.
11. Pierce, G.F., et al., Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol, 1989. 109(1): p. 429-40.
12. Hom, D.B. and R.H. Maisel, Angiogenic growth factors: their effects and potential in soft tissue wound healing. Ann Otol Rhinol Laryngol, 1992. 101(4): p. 349-54.
13. Takikawa, M., et al., Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. Dermatol Surg, 2011. 37(12): p. 1721-9.
14. Akeda K, An HS, Pichika R, Attawia M, Thonar EJ, Lenz ME, Uchida A, Masuda K. Platelet-rich plasma (PRP) stimulates the extracellular matrix metabolism of porcine nucleus pulposus and anulus fibrosus cells cultured in alginate beads. Spine (Phila Pa 1976). 2006 Apr 20;31(9):959-66. doi: 10.1097/01.brs.0000214942.78119.24. PMID: 16641770.
15. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. doi: 10.1016/j.cell.2006.07.024. Epub 2006 Aug 10. PMID: 16904174.
16. Merhi, Z., et al., Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization. Clinical and experimental reproductive medicine, 2022. 49(3), 210–214.
17. Garavelas A, Mallis P, Michalopoulos E, Nikitos E. Clinical Benefit of Autologous Platelet-Rich Plasma Infusion in Ovarian Function Rejuvenation: Evidence from a Before-After Prospective Pilot Study. Medicines. 2023; 10(3):19.
18. Sfakianoudis K, Simopoulou M, Grigoriadis S, Pantou A, Tsioulou P, Maziotis E, Rapani A, Giannelou P, Nitsos N, Kokkali G, et al. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. Journal of Clinical Medicine. 2020; 9(6):1809.
19. Seyyed Anvari S, Dehgan GH, Razi M. Preliminary Findings of Platelet-Rich Plasma-Induced Ameliorative Effect on Polycystic Ovarian Syndrome. Cell J. 2019 Oct;21(3):243-252. doi: 10.22074/cellj.2019.5952. Epub 2019 Jun 15. PMID: 31210429; PMCID: PMC6582424.
20. Anitua, E., Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants, 1999. 14(4): p. 529-35.
21. Weibrich, G., et al., Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone, 2004. 34(4): p. 665-71.
22. Sanchez, M., et al., Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc, 2003. 35(10): p. 1648-52.
23. McCarrel, T.M., T. Minas, and L.A. Fortier, Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am, 2012. 94(19): p. e143(1-8).
24. Filardo, G., et al., Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc, 2012. 20(10): p. 2082-91.
25. Sanchez, M., et al., A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy, 2012. 28(8): p. 1070-8.
26. Alio, J.L., et al., Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res, 2007. 39(3): p. 124-9
27. Alio, J.L., et al., Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome. J Ophthalmol, 2017. 2017: p. 2457620.
28. Anitua, E., et al., Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater, 2008. 84(2): p. 415-21.
29. Anitua, E., M. Sanchez, and G. Orive, Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev, 2010. 62(7-8): p. 741-52.
30. Anitua, E. and G. Orive, Endogenous regenerative technology using plasma- and platelet-derived growth factors. J Control Release, 2012. 157(3): p. 317-20.
31. Chang, Y., et al., Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med, 2015. 8(1): p. 1286-90.
32. Chang, Y., et al., Autologous platelet-rich plasma infusion improves clinical pregnancy rate in frozen embryo transfer cycles for women with thin endometrium. Medicine (Baltimore), 2019. 98(3): p. e14062.
33. Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol. 2018 Sep;34(9):756-760. doi: 10.1080/09513590.2018.1445219. Epub 2018 Feb 28. PMID: 29486615.
34. Petryk N, Petryk M. Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)-a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment. Reprod Sci. 2020 Nov;27(11):1975-1982. doi: 10.1007/s43032-020-00266-8. Epub 2020 Jul 22. PMID: 32700285.
35. Cakiroglu Y, Saltik A, Yuceturk A, Karaosmanoglu O, Kopuk SY, Scott RT, Tiras B, Seli E. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging (Albany NY). 2020 Jun 5;12(11):10211-10222. doi: 10.18632/aging.103403. Epub 2020 Jun 5. PMID: 32507764; PMCID: PMC7346073.
36. Hsu CC, Hsu L, Hsu I, Chiu YJ, Dorjee S. Live Birth in Woman With Premature Ovarian Insufficiency Receiving Ovarian Administration of Platelet-Rich Plasma (PRP) in Combination With Gonadotropin: A Case Report. Front Endocrinol (Lausanne). 2020 Feb 19;11:50. doi: 10.3389/fendo.2020.00050. PMID: 32140135; PMCID: PMC7043014.
37. Tandulwadkar S, Karthick MS. Combined Use of Autologous Bone Marrow-derived Stem Cells and Platelet-rich Plasma for Ovarian Rejuvenation in Poor Responders. J Hum Reprod Sci. 2020 Jul-Sep;13(3):184-190. doi: 10.4103/jhrs.JHRS_130_19. Epub 2020 Oct 27. PMID: 33311903; PMCID: PMC7727891.
38. Stojkovska S, Dimitrov G, Stamenkovska N, Hadzi-Lega M, Petanovski Z. Live Birth Rates in Poor Responders’ Group after Previous Treatment with Autologous Platelet-Rich Plasma and Low Dose Ovarian Stimulation Compared with Poor Responders Used Only Low Dose Ovarian Stimulation Before in Vitro Fertilization. Open Access Maced J Med Sci. 2019 Sep 14;7(19):3184-3188. doi: 10.3889/oamjms.2019.825. PMID: 31949513; PMCID: PMC6953937.
39. Tülek F, Kahraman A. The effects of intra-ovarian autologous platelet rich plasma injection on IVF outcomes of poor responder women and women with premature ovarian insufficiency. J Turk Ger Gynecol Assoc. 2022 Mar 8;23(1):14-21. doi: 10.4274/jtgga.galenos.2021.2021.0134. Epub 2021 Dec 6. PMID: 34866374; PMCID: PMC8907433.
40. D H Barad, D F Albertini, E Molinari, N Gleicher, Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study, Human Reproduction Open, Volume 2022, Issue 3, 2022, hoac027
41. Barrenetxea G, Celis R, Barrenetxea J, Martínez E, De Las Heras M, Gómez O, Aguirre O. Intraovarian platelet-rich plasma injection and IVF outcomes in patients with poor ovarian response: a double-blind randomized controlled trial. Hum Reprod. 2024 Apr 3;39(4):760-769. doi: 10.1093/humrep/deae038. PMID: 38423539.
42. Sagai M, Bocci V. Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress? Med Gas Res. 2011 Dec 20;1:29. doi: 10.1186/2045-9912-1-29. PMID: 22185664; PMCID: PMC3298518.
43. Boczkowska-Radziwon B, Olbromski PJ, Rogowska A, Bujno M, Myśliwiec M, Żebrowska A, Średziński D, Polityńska B, Wojtukiewicz MZ, Radziwon P. Ozonation of Whole Blood Results in an Increased Release of Microparticles from Blood Cells. Biomolecules. 2022 Jan 21;12(2):164. doi: 10.3390/biom12020164. PMID: 35204669; PMCID: PMC8961535.
44. Sfakianoudis, K., et al., Novel Approaches in Addressing Ovarian Insufficiency in 2019: Are We There Yet? Cell Transplant, 2020. 29: p. 963689720926154.
45. Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number); Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26. PMID: 26921622.
46. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098. PMID: 14688154.
47. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th ed. WHO Press; Geneva, Switzerland: 2010.
48. Farimani, M., et al., A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP). Mol Biol Rep, 2019. 46(2): p. 1611-1616.